AviadoBio Ltd. is preparing to take its lead gene therapy program to the clinic in a subset of dementia patients who could benefit from the greater precision of intra-thalamic delivery.
The firm was spun out of research conducted by neuroscientist Chris Shaw at King’s College, London. Shaw’s team focuses on...







